Results 131 to 140 of about 1,158 (177)
Some of the next articles are maybe not open access.
Teduglutide in Crohn's disease
Expert Opinion on Biological Therapy, 2013The currently available medications for treatment of Crohn's disease (CD) include aminosalicylates, corticosteroids, antibiotics, immunomodulators and biologic agents (infliximab, certolizumab pegol, adalimumab and natalizumab). These agents target the immune and inflammatory pathways of CD, while there is a shortage of agents that target the barrier ...
Wojciech, Blonski +3 more
openaire +2 more sources
Teduglutide for pediatric short bowel syndrome patients
Expert Review of Gastroenterology & Hepatology, 2021Introduction: The goal for pediatric short bowel syndrome (SBS) patients is intestinal adaptation. Until recently, the medical management of pediatric SBS has centered on the prevention and treatment of complications in order to allow time for adaptation.
Beatrice E. Rosete +2 more
openaire +2 more sources
Teduglutide for the Treatment of Short Bowel Syndrome
Annals of Pharmacotherapy, 2014Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of the newly approved drug, teduglutide, for the treatment of short bowel syndrome (SBS). Data Sources: Literature was retrieved through PubMed (1966-March 2014) using the search term
Sheila M, Wilhelm +3 more
openaire +2 more sources
Teduglutide: A Review in Short Bowel Syndrome
Drugs, 2017Subcutaneous teduglutide (Revestive®), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged ≥1 year who are stable following a period of postsurgical intestinal adaptation.
Esther S, Kim, Susan J, Keam
openaire +2 more sources
Pharmacokinetics of teduglutide in subjects with renal impairment
European Journal of Clinical Pharmacology, 2012Teduglutide is a recombinant analogue of human glucagon-like peptide-2 that has recently been approved for the treatment of short bowel syndrome in adults. This study was designed to study the influence of renal function and age on teduglutide pharmacokinetics.This was an open-label study with six parallel groups (6 subjects each).
Rüdiger, Nave +8 more
openaire +2 more sources
Teduglutide for the treatment of short bowel syndrome
Expert Review of Gastroenterology & Hepatology, 2011Extensive resection of the intestine impairs its absorptive capacity and results in short bowel syndrome when the nutritional equilibrium is compromised. The remnant intestine adapts structurally to compensate, but nutritional autonomy cannot be achieved in patients with intestinal failure, requiring intravenous fluids and parenteral nutrition (PN) for
Kishore, Vipperla, Stephen J, O'Keefe
openaire +2 more sources
Teduglutide for the Treatment of Short Bowel Syndrome
Annals of Pharmacotherapy, 2006Objective: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS). Data Sources: Clinical literature ...
Marcus, Ferrone, James S, Scolapio
openaire +2 more sources
Teduglutide and Intestinal Permeability in Short Bowel Syndrome
Journal of Parenteral and Enteral Nutrition, 2016N ...
Montalto, Massimo +1 more
openaire +3 more sources
A Thorough QT Study of Teduglutide in Healthy Subjects
Clinical Pharmacology in Drug Development, 2012AbstractTeduglutide, an analog of the endogenous hormone glucagon‐like peptide‐2, is currently being developed for the treatment of short bowel syndrome. This study investigated the potential effects of teduglutide on cardiac conduction and repolarization.
Manfred, Hartmann +7 more
openaire +2 more sources